Compare ProShares Ultra Silver ETF (AGQ) vs Summit Therapeutics Inc (SMMT) Price & Performance

AGQ, the ProShares Ultra Silver ETF, trades at $81.00, down 1.07% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The leveraged ETF structure amplifies silver price moves, with recent volatility highlighted by a 9.39% surge on silver rallies but a 16% crash in June 2026. Financial ratios are not applicable as this is an ETF tracking silver futures.

Outlook hinges on silver price direction, offering amplified gains if silver rallies but severe decay in downturns. Key risks include structural decay from daily leverage resets and silver's sensitivity to Fed policy. Investors must weigh high volatility against silver's bullish momentum.

Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.

The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.